Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 6/2010

01-06-2010 | Breast Oncology

Liver Resection for Multimodal Treatment of Breast Cancer Metastases: Identification of Prognostic Factors

Authors: Katrin Hoffmann, MD, Clemens Franz, Ulf Hinz, Peter Schirmacher, MD, Christian Herfarth, MD, Michael Eichbaum, MD, Markus W. Büchler, MD, Peter Schemmer, MD

Published in: Annals of Surgical Oncology | Issue 6/2010

Login to get access

Abstract

Background

Liver resection (LR) within a multimodal treatment concept of hepatic metastases (HM) that results from breast cancer has been controversially discussed. The aim of this study was to evaluate the outcome of LR in patients with hepatic breast cancer metastases.

Methods

Prospectively collected data from 41 consecutive patients who underwent LR for HM between 1999 and 2008 were analyzed retrospectively. Univariate and multivariate analyses were performed to assess potential prognostic factors.

Results

Segmental resection was performed in 46% and major hepatectomy in 54% of patients. The postoperative mortality rate was 0%. At a median follow-up of 34 months, 26 patients were alive. The median and 5-year overall survival rates after LR were 58 months and 48%, respectively. The median and 5-year disease-free survivals were 34 months and 31%, respectively. The intrahepatic recurrence-free 5-year survival was 62%. The median survival from time of diagnosis of HM was 79 months. The positive resection margin as well as a disease-free interval between the treatment of the primary tumor and the diagnosis of HM < 1 year were independent predictors of overall survival.

Conclusions

LR of hepatic breast cancer metastases within a multimodal treatment concept is a safe procedure in well-selected patients. Both a short time interval to the development of HM and positive resection margins after LR are strongly associated with worse long-term survival.
Literature
1.
Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002. Cancer incidence, mortality and prevalence worldwide. IARC Cancer Base No. 5. Version 2.0. Lyon, France: IARC Press, 2004.
2.
Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347:1233–41.CrossRefPubMed
3.
Fisher B, Jeong JH, Anderson S, et al. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002;347:567–75.CrossRefPubMed
4.
Jardines L, Callans LS, Torosian MH. Recurrent breast cancer: presentation, diagnosis, and treatment. Semin Oncol. 1993;20:538–47.PubMed
5.
Insa A, Lluch A, Prosper F, et al. Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: analysis of 439 patients. Breast Cancer Res Treat. 1999;56:67–78.CrossRefPubMed
6.
Eichbaum MH, Kaltwasser M, Bruckner T, et al. Prognostic factors for patients with liver metastases from breast cancer. Breast Cancer Res. Treat. 2006;96:53–62.CrossRefPubMed
7.
Fong Y, Salo J. Surgical therapy of hepatic colorectal metastasis. Semin Oncol. 1999;26:514–23.PubMed
8.
Fuhrman GM, Curley SA, Hohn DC, Roh MS. Improved survival after resection of colorectal liver metastases. Ann Surg Oncol. 1995;2:537–41.CrossRefPubMed
9.
Seifert JK, Weigel TF, Gonner U, Bottger TC, Junginger T. Liver resection for breast cancer metastases. Hepatogastroenterology. 1999;46:2935–40.PubMed
10.
Vlastos G, Smith DL, Singletary SE, et al. Long-term survival after an aggressive surgical approach in patients with breast cancer hepatic metastases. Ann Surg Oncol. 2004;11:869–74.CrossRefPubMed
11.
Yoshimoto M, Tada T, Saito M, et al. Surgical treatment of hepatic metastases from breast cancer. Breast Cancer Res Treat. 2000;59:177–84.CrossRefPubMed
12.
Pocard M, Pouillart P, Asselain B, Salmon R. Hepatic resection in metastatic breast cancer: results and prognostic factors. Eur J Surg Oncol. 2000;26:155–9.CrossRefPubMed
13.
Elias D, Maisonnette F, Druet-Cabanac M, et al. An attempt to clarify indications for hepatectomy for liver metastases from breast cancer. Am J Surg. 2003;185:158–64.CrossRefPubMed
14.
Adam R, Aloia T, Krissat J, et al. Is liver resection justified for patients with hepatic metastases from breast cancer? Ann Surg. 2006;244:897–907.CrossRefPubMed
15.
Poon RT, Fan ST, Lo CM, et al. Improving perioperative outcome expands the role of hepatectomy in management of benign and malignant hepatobiliary diseases: analysis of 1222 consecutive patients from a prospective database. Ann Surg. 2004;240:698–708.PubMed
16.
Jarnagin WR, Gonen M, Fong Y, et al. Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg. 2002;236:397–406.CrossRefPubMed
17.
Schemmer P, Friess H, Hinz U, et al. Stapler hepatectomy is a safe dissection technique: analysis of 300 patients. World J Surg. 2006;30:419–30.CrossRefPubMed
18.
Sakamoto Y, Yamamoto J, Yoshimoto M, et al. Hepatic resection for metastatic breast cancer: prognostic analysis of 34 patients. World J Surg. 2005;29:524–7.CrossRefPubMed
19.
Sobin LH, Wittekind CH. TNM classification of malignant tumours. 6th ed. New York: Wiley Liss, 2002.
20.
Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.CrossRefPubMed
21.
Goldhirsch A, Gelber RD, Castiglione M. Relapse of breast cancer after adjuvant treatment in premenopausal and perimenopausal women: patterns and prognoses. J Clin Oncol. 1988;6:89–97.PubMed
22.
Kiang DT, Kennedy BJ, Younger J, et al. Alternating chemotherapy regimens for patients with metastatic breast cancer. A pilot study based on tumor marker kinetics. Cancer and Leukemia Group B. Cancer. 1995;75:826–30.CrossRefPubMed
23.
Piccart MJ, Raymond E, Aapro M, Eisenhauer EA, Cvitkovic E. Cytotoxic agents with activity in breast cancer patients previously exposed to anthracyclines: current status and future prospects. Eur J Cancer. 1995;31A(Suppl 7):S1–10.CrossRefPubMed
24.
O’Reilly SM, Richards MA, Rubens RD. Liver metastases from breast cancer: the relationship between clinical, biochemical and pathological features and survival. Eur J Cancer. 1990;26:574–7.CrossRefPubMed
25.
Wyld L, Gutteridge E, Pinder SE, et al. Prognostic factors for patients with hepatic metastases from breast cancer. Br J Cancer. 2003;89:284–90.CrossRefPubMed
26.
Kondo S, Katoh H, Omi M, et al. Hepatectomy for metastases from breast cancer offers the survival benefit similar to that in hepatic metastases from colorectal cancer. Hepatogastroenterology. 2000;47:1501–3.PubMed
27.
Maksan SM, Lehnert T, Bastert G, Herfarth C. Curative liver resection for metastatic breast cancer. Eur. J. Surg. Oncol. 2000;26:209–12.CrossRefPubMed
28.
Selzner M, Morse MA, Vredenburgh JJ, Meyers WC, Clavien PA. Liver metastases from breast cancer: long-term survival after curative resection. Surgery. 2000;127:383–9.CrossRefPubMed
29.
Carlini M, Lonardo MT, Carboni F, et al. Liver metastases from breast cancer. Results of surgical resection. Hepatogastroenterology. 2002;49:1597–601.PubMed
30.
Ercolani G, Grazi GL, Ravaioli M, et al. The role of liver resections for noncolorectal, nonneuroendocrine metastases: experience with 142 observed cases. Ann. Surg. Oncol. 2005;12:459–66.CrossRefPubMed
31.
Furka A, Halasz L, Szentkereszty Z, et al. Surgical treatment of liver metastases from breast cancer. Hepatogastroenterology. 2008;55:1416–8.PubMed
32.
Kollmar O, Moussavian MR, Richter S, Bolli M, Schilling MK. Surgery of liver metastasis in gynecological cancer—indication and results. Onkologie. 2008;31:375–9.CrossRefPubMed
33.
d’Annibale M, Piovanello P, Cerasoli V, Campioni N. Liver metastases from breast cancer: the role of surgical treatment. Hepatogastroenterology. 2005;52:1858–62.PubMed
34.
Thelen A, Benckert C, Jonas S, et al. Liver resection for metastases from breast cancer. J Surg Oncol. 2008;97:25–9.CrossRefPubMed
35.
Krag DN, Ashikaga T, Moss TJ, et al. Breast cancer cells in the blood: a pilot study. Breast J. 1999;5:354–8.CrossRefPubMed
36.
Beitsch PD, Clifford E. Detection of carcinoma cells in the blood of breast cancer patients. Am J Surg. 2000;180:446–8.CrossRefPubMed
37.
Raab R, Nussbaum KT, Behrend M, Weimann A. Liver metastases of breast cancer: results of liver resection. Anticancer Res. 1998;18(3C):2231–3.PubMed
38.
Lubrano J, Roman H, Tarrab S, et al. Liver resection for breast cancer metastasis: does it improve survival? Surg Today. 2008;38:293–9.CrossRefPubMed
39.
Caralt M, Bilbao I, Cortes J, et al. Hepatic resection for liver metastases as part of the “oncosurgical” treatment of metastatic breast cancer. Ann. Surg. Oncol. 2008;15:2804–10.CrossRefPubMed
Metadata
Title
Liver Resection for Multimodal Treatment of Breast Cancer Metastases: Identification of Prognostic Factors
Authors
Katrin Hoffmann, MD
Clemens Franz
Ulf Hinz
Peter Schirmacher, MD
Christian Herfarth, MD
Michael Eichbaum, MD
Markus W. Büchler, MD
Peter Schemmer, MD
Publication date
01-06-2010
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 6/2010
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-010-0931-5

Other articles of this Issue 6/2010

Annals of Surgical Oncology 6/2010 Go to the issue

Colorectal Cancer

Multicentric Study on Robotic Tumor-Specific Mesorectal Excision for the Treatment of Rectal Cancer

Healthcare Policy and Outcomes

Do Practice Patterns Reflect Practice Guidelines?

Gastrointestinal Oncology

In Reply: Does Metastatic Lymph Node Ratio Really Suit for Prognostic Prediction of the D1 Lymphadenectomy?

Breast Oncology

When is Age More Than Just a Number?

Gastrointestinal Oncology

Chemoradiotherapy in Adenocarcinoma of the Stomach or Esophagus

Thoracic Oncology

Age does not Preclude an Esophagectomy…If Only it were that Simple